Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 23;9:719192. doi: 10.3389/fcell.2021.719192

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Li, Wang, Lan, Wu, Evans, Ruiz, Yan, Zhou, Oliveira, Reis, Hu, Chen, Behrens, He and Zhang.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The inhibition of PARP1 can significantly enhance the DNA damage and inhibit BER of Oxaliplatin-resistant GC. (A) Comparison of γH2AX expression in Olaparib + Oxaliplatin, Oxaliplatin, Olaparib, and the blank control group and the MKN74, SNU719, AGS resistant strains, and their corresponding wild-type cell lines at different times. Comparison of XRCC1 expression in Olaparib + Oxaliplatin, Oxaliplatin, Olaparib, and the blank control group in MKN74, SNU719, and AGS Oxaliplatin resistance strains. (B) Immunofluorescent comparison of γH2AX expression in Olaparib + Oxaliplatin, Oxaliplatin, Olaparib, and the blank control group and the MKN74, SNU719, AGS resistant strains, and their corresponding wild-type cell lines at different times. (C) Ratio of γH2AX + cells in MKN74, SNU719, AGS Oxaliplatin resistance strains, and their corresponding wild-type cell line (B,D) immunofluorescent comparison of XRCC1 expression in Olaparib + Oxaliplatin, Oxaliplatin, Olaparib, and the blank control group in MKN74, SNU719, and AGS Oxaliplatin resistance strains. The scale represents 2 um. (E) Ratio of XRCC1 cells in MKN74, SNU719, AGS Oxaliplatin resistance strain and their respective wild-type cell lines (D), respectively. The Student’s t test was used for statistical analysis. Error bars indicate mean ± standard deviation. OXA, Oxaliplatin. OLP, Olaparib. CON, control group. AGSR, AGS Oxaliplatin resistance. SNU719R, SNU719 Oxaliplatin resistance. MKN74R, MKN74 Oxaliplatin resistance. *< 0.05, **< 0.01, and ***< 0.001. All experiments were repeated three times.